Inhibits angiotensin-converting enzyme (ACE) with a Ki of 61.8 uM, and targets B1 bradykinin receptors (BDKRB1). In vivo, induces hyperalgesic effects in living rats after intraplantar injection. Expressed by the venom gland. Is hydrolyzed by angiotensin-converting enzyme (ACE) by only 6.7% (compared to bradykinin). Is neither able to contract smooth muscle preparation (ileum), not to potentiate bradykinin (PubMed:19716363) and does not provoke inflammation in rats (PubMed:11306139). Belongs to the bradykinin-related peptide family.